Comparative Pharmacology
Head-to-head clinical analysis: ARICEPT versus MESTINON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARICEPT versus MESTINON.
ARICEPT vs MESTINON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine levels in the synaptic cleft of the central nervous system.
Inhibits acetylcholinesterase, preventing breakdown of acetylcholine and increasing its concentration at cholinergic synapses, thereby enhancing neuromuscular transmission.
Initial: 5 mg orally once daily for 4-6 weeks; may increase to 10 mg once daily. Maximum: 10 mg per day. Route: oral. Frequency: once daily.
Myasthenia gravis: 60-150 mg orally every 3-4 hours, up to 1.2 g/day. Extended-release: 180-540 mg orally once or twice daily.
None Documented
None Documented
70 hours (terminal elimination half-life; steady-state reached in 15-21 days; once-daily dosing appropriate)
The terminal elimination half-life is approximately 1.5 to 2 hours in adults. In patients with renal impairment, half-life may be prolonged (up to 6-10 hours in severe impairment), necessitating dose adjustment.
Renal (57% unchanged drug, 17% as metabolites), fecal (30%), biliary (minimal)
Renal excretion of unchanged drug and metabolites accounts for approximately 80-90% of elimination, with a small fraction (10-20%) eliminated in feces via biliary secretion.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor